Jason Gerberry
Stock Analyst at B of A Securities
(3.92)
# 619
Out of 5,055 analysts
163
Total ratings
59.83%
Success rate
6.92%
Average return
Main Sectors:
Stocks Rated by Jason Gerberry
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OCS Oculis Holding AG | Maintains: Buy | $30 → $29 | $19.15 | +51.44% | 4 | Nov 13, 2025 | |
| IONS Ionis Pharmaceuticals | Maintains: Buy | $81 → $83 | $73.26 | +13.30% | 6 | Sep 23, 2025 | |
| AMPH Amphastar Pharmaceuticals | Maintains: Neutral | $28 → $32 | $26.02 | +22.98% | 2 | Aug 26, 2025 | |
| IMVT Immunovant | Maintains: Buy | $33 → $30 | $24.30 | +23.46% | 6 | Aug 12, 2025 | |
| BHVN Biohaven | Maintains: Buy | $50 → $49 | $8.27 | +492.50% | 2 | Aug 12, 2025 | |
| AXSM Axsome Therapeutics | Maintains: Buy | $173 → $176 | $145.56 | +20.91% | 6 | Aug 5, 2025 | |
| PROK ProKidney | Downgrades: Underperform | $3 → $1 | $2.25 | -55.56% | 4 | Jun 30, 2025 | |
| LQDA Liquidia | Maintains: Buy | $25 → $23 | $28.40 | -19.01% | 2 | Jun 11, 2025 | |
| EXEL Exelixis | Maintains: Neutral | $45 → $46 | $42.42 | +8.44% | 3 | Jun 5, 2025 | |
| TEVA Teva Pharmaceutical Industries | Maintains: Buy | $20 → $22 | $24.59 | -10.53% | 14 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $157 → $137 | $48.34 | +183.41% | 9 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $11 → $10 | $10.66 | -6.19% | 3 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30 | $22.56 | +32.98% | 2 | Jan 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $84 → $100 | $90.34 | +10.69% | 5 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $24 | $6.62 | +262.54% | 1 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $41 → $31 | $30.76 | +0.78% | 6 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $600 → $550 | $3.74 | +14,605.88% | 3 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $27 → $29 | $29.33 | -1.13% | 9 | Jan 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $29 → $37 | $40.15 | -7.85% | 2 | Jan 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $52 → $56 | $40.61 | +37.90% | 2 | Jan 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $30 | $33.97 | -11.69% | 2 | Jan 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $204 → $217 | $170.09 | +27.58% | 5 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $100 → $50 | $8.70 | +474.71% | 6 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $450 → $500 | $1,021.70 | -51.06% | 15 | May 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $9 | $1.23 | +631.71% | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $37 → $25 | $7.65 | +226.80% | 3 | Oct 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $45 → $5 | $2.05 | +143.90% | 2 | Dec 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $27 | $6.13 | +340.46% | 4 | Mar 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $20 | $1.13 | +1,669.91% | 1 | Jul 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $170 → $100 | $3.73 | +2,580.97% | 1 | Jul 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $95 | $234.00 | -59.40% | 10 | May 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $60 | $46.81 | +28.18% | 7 | Oct 17, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $37 | $25.08 | +47.53% | 4 | Oct 17, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $90 | $92.86 | -3.08% | 11 | Oct 17, 2019 |
Oculis Holding AG
Nov 13, 2025
Maintains: Buy
Price Target: $30 → $29
Current: $19.15
Upside: +51.44%
Ionis Pharmaceuticals
Sep 23, 2025
Maintains: Buy
Price Target: $81 → $83
Current: $73.26
Upside: +13.30%
Amphastar Pharmaceuticals
Aug 26, 2025
Maintains: Neutral
Price Target: $28 → $32
Current: $26.02
Upside: +22.98%
Immunovant
Aug 12, 2025
Maintains: Buy
Price Target: $33 → $30
Current: $24.30
Upside: +23.46%
Biohaven
Aug 12, 2025
Maintains: Buy
Price Target: $50 → $49
Current: $8.27
Upside: +492.50%
Axsome Therapeutics
Aug 5, 2025
Maintains: Buy
Price Target: $173 → $176
Current: $145.56
Upside: +20.91%
ProKidney
Jun 30, 2025
Downgrades: Underperform
Price Target: $3 → $1
Current: $2.25
Upside: -55.56%
Liquidia
Jun 11, 2025
Maintains: Buy
Price Target: $25 → $23
Current: $28.40
Upside: -19.01%
Exelixis
Jun 5, 2025
Maintains: Neutral
Price Target: $45 → $46
Current: $42.42
Upside: +8.44%
Teva Pharmaceutical Industries
May 8, 2025
Maintains: Buy
Price Target: $20 → $22
Current: $24.59
Upside: -10.53%
Apr 1, 2025
Maintains: Buy
Price Target: $157 → $137
Current: $48.34
Upside: +183.41%
Feb 28, 2025
Maintains: Underperform
Price Target: $11 → $10
Current: $10.66
Upside: -6.19%
Jan 9, 2025
Reiterates: Buy
Price Target: $30
Current: $22.56
Upside: +32.98%
Nov 6, 2024
Maintains: Buy
Price Target: $84 → $100
Current: $90.34
Upside: +10.69%
Sep 10, 2024
Maintains: Buy
Price Target: $20 → $24
Current: $6.62
Upside: +262.54%
Apr 1, 2024
Downgrades: Underperform
Price Target: $41 → $31
Current: $30.76
Upside: +0.78%
Mar 25, 2024
Maintains: Buy
Price Target: $600 → $550
Current: $3.74
Upside: +14,605.88%
Jan 2, 2024
Maintains: Neutral
Price Target: $27 → $29
Current: $29.33
Upside: -1.13%
Jan 2, 2024
Maintains: Buy
Price Target: $29 → $37
Current: $40.15
Upside: -7.85%
Jan 2, 2024
Maintains: Buy
Price Target: $52 → $56
Current: $40.61
Upside: +37.90%
Jan 2, 2024
Downgrades: Underperform
Price Target: $30
Current: $33.97
Upside: -11.69%
Aug 10, 2023
Maintains: Buy
Price Target: $204 → $217
Current: $170.09
Upside: +27.58%
Aug 8, 2023
Downgrades: Underperform
Price Target: $100 → $50
Current: $8.70
Upside: +474.71%
May 24, 2023
Maintains: Buy
Price Target: $450 → $500
Current: $1,021.70
Upside: -51.06%
Dec 12, 2022
Downgrades: Underperform
Price Target: $9
Current: $1.23
Upside: +631.71%
Oct 14, 2022
Downgrades: Underperform
Price Target: $37 → $25
Current: $7.65
Upside: +226.80%
Dec 2, 2021
Downgrades: Underperform
Price Target: $45 → $5
Current: $2.05
Upside: +143.90%
Mar 24, 2021
Downgrades: Underperform
Price Target: $27
Current: $6.13
Upside: +340.46%
Jul 16, 2020
Initiates: Neutral
Price Target: $20
Current: $1.13
Upside: +1,669.91%
Jul 15, 2020
Downgrades: Neutral
Price Target: $170 → $100
Current: $3.73
Upside: +2,580.97%
May 18, 2020
Reinstates: Neutral
Price Target: $95
Current: $234.00
Upside: -59.40%
Oct 17, 2019
Reinstates: Buy
Price Target: $60
Current: $46.81
Upside: +28.18%
Oct 17, 2019
Reinstates: Neutral
Price Target: $37
Current: $25.08
Upside: +47.53%
Oct 17, 2019
Reinstates: Neutral
Price Target: $90
Current: $92.86
Upside: -3.08%